Tirzepatide research has more than one verdict

Tirzepatide vs semaglutide depends on the question

In SURPASS-2’s diabetes comparison, 1,879 adults with type 2 diabetes were followed for 40 weeks. HbA1c—the blood marker of glucose over recent months—fell by 2.01, 2.24 and 2.30 percentage points at tirzepatide study doses of 5, 10 and 15 mg. The reduction with semaglutide 1 mg was 1.86 percentage points. Tirzepatide was superior at all three doses, and weight also fell more. The study was open-label: participants and staff knew the treatment.

SURMOUNT-5 asked the obesity question directly, in 751 adults without type 2 diabetes over 72 weeks, using maximum tolerated doses. Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide. It too was open-label.

I accept the superiority findings for those measured outcomes. Extending that conclusion to “better for everybody” is a leap I cannot defend. These findings apply to the particular populations and dose comparisons studied. The weight-loss entry places the second result beside placebo and withdrawal evidence.

The comparator’s dose is part of a head-to-head result. “Against semaglutide” still requires the dose detail.

A heart result is not always a heart-failure result

SUMMIT studied heart failure with preserved ejection fraction and obesity. Preserved ejection fraction means the heart still pumps out a normal proportion of its blood; heart failure can nevertheless occur because filling is impaired. Tirzepatide reduced heart-failure events and improved clinical status versus placebo.

SURPASS-CVOT compared major cardiovascular outcomes with dulaglutide in adults with type 2 diabetes and established cardiovascular disease. The current record reports tirzepatide as no worse than the comparator at preventing major cardiovascular events. That is a different claim from superiority, and a different question from SUMMIT.

I give this distinction a lot of weight. “Good for the heart” can swallow both results and lose what each trial actually established. My favorable judgment of SUMMIT does not authorize me to upgrade the other trial’s conclusion.

The kidney evidence comes with a population

The SURPASS-4 kidney analysis found slower deterioration in kidney filtering and less albumin in the urine with tirzepatide than with insulin glargine. Its participants had type 2 diabetes and high cardiovascular risk. This substudy leaves kidney protection for everyone with or without diabetes unproven.

The 24-hour ambulatory blood-pressure study found lower systolic pressure versus placebo in adults with a BMI of at least 27. Measuring across a day adds something a single office reading cannot, but lower pressure and fewer major cardiovascular events remain distinct outcomes.

My enthusiasm narrows at the population boundary. These findings enlarge the record; they do not erase the entry criteria.

A kidney substudy in high-risk type 2 diabetes does not settle a claim about people without diabetes.

Sleep recordings and liver biopsies carry different testimony

The sleep-apnea trials studied adults with obesity and moderate-to-severe obstructive sleep apnea. Tirzepatide reduced the rate of breathing interruptions as weight fell. This is clinical evidence with a measured sleep outcome, distinct from community accounts of more refreshing sleep.

In the liver-fibrosis trial, adults had metabolic dysfunction-associated steatohepatitis, an inflammatory form of fatty liver disease, with moderate-to-severe fibrosis. Liver biopsies showed disease resolution without worsening fibrosis more often with tirzepatide than placebo. Tissue findings are meaningful; they are not the same as evidence that someone feels better or a new approved indication.

That distinction sets the limits of my enthusiasm for adding another organ to the list. The test’s endpoint tells us what kind of testimony it can give.

The explanation is still being argued

The cell and islet signaling experiments give a reason to investigate the uneven GIP/GLP-1 partnership. The review of actions beyond the pancreas offers a wider physiological framework. Neither proves how much of each human result is due to weight loss, to receptor activity apart from weight, or to their interaction.

Much of the strongest efficacy evidence is manufacturer-funded. The trial still deserves assessment on its findings and design, with its funding in view. My remaining interest is in durability, tolerability and objective function—questions for which a compelling mechanism alone supplies no answer.

The source register and effects record belong alongside the efficacy findings. A verdict gets more useful when its scope gets more precise.